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Background: In the process of hepatic fibrosis, hepatic stellate cells (HSCs) can be activated by many inflammatory
cytokines. The transforming growth factor-β1 (TGF-β1) is one of the main profibrogenic mediators. Recently, some
studies have also shown that microRNAs (miRNAs) play essential roles in the progress of liver fibrosis by being
involved in the differentiation, fat metabolism and ECM production of HSCs.
Methods: The expression of miR-454 in LX-2 cells treated with TGF-β1 and in the fibrotic livers with Schistosoma
japonicum infection was detected by qRT-PCR. The role of miR-454 on LX-2 cells was then analyzed by Western blot,
flow cytometry and luciferase assay.
Results: The results showed that the expression of miR-454 was down-regulated in the TGF-β1-treated LX-2 cells
and miR-454 could inhibit the activation of HSCs by directly targeting Smad4. However, we found that miR-454
had no effect on cell cycle and cell proliferation in TGF-β1-treated LX-2. Besides these, miR-454 was found to be
regulated in the process of Schistosoma japonicum infection.
Conclusions: All the results suggested that miR-454 could provide a novel therapeutic approach for treating liver
fibrosis, especially the liver fibrosis induced by Schistosoma japonicum.
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Hepatic fibrosis, characterized by the excessive depos-
ition of extracellular matrix (ECM), occurs in many
types of liver diseases and reflects a balance between
liver repair and scar formation [1]. Inflammation plays a
key role in the development of liver fibrosis. During the
progression of liver fibrosis, macrophages, lymphocytes,
fibroblasts and other inflammatory cells can be stimu-
lated by etiological factors [2]. Hepatic stellate cells
(HSCs), which have been considered to be the major
effector cells, can be activated by many inflammatory
cytokines and undergo myofibroblastic transdifferentia-
tion in the progress of liver fibrosis [1,3]. During this* Correspondence: yinongduan@gmail.com
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unless otherwise stated.progress, the transforming growth factor-β1 (TGF-β1) is
recognized as one of the main profibrogenic mediators
[4,5] and plays a key role in the development of inflam-
mation and subsequent liver fibrosis.
MicroRNAs (miRNAs) are endogenous, small and
noncoding RNAs, which have the ability to regulate gene
expression in a mature form by binding to the 3′-un-
translated region (3′-UTR) of target mRNAs and repres-
sing translation or inducing mRNA cleavage [6,7].
Previous studies have revealed that miRNAs play indis-
pensable roles in the progress of liver fibrosis by being
involved in the differentiation, fat metabolism and ECM
production of HSCs [8,9] and the proliferation and
apoptosis of HSCs [10-12]. Over-expression of miR-146a
can suppress TGF-β1-induced HSC proliferation and
induce HSC apoptosis [11]. miR-15b and miR-16 are
essential for HSC apoptosis by targeting Bcl-2 through
the caspase signaling pathway [12]. miR-335 can also. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(TNC) expression [9]. Recently, the miR-454 family has
been reported to be up-regulated in human colorectal
cancer tissues and cell lines by targeting Smad4 [13].
However, there are no prior studies in which the effect
of miR-454 on TGF-β1-induced HSC activation is con-
sidered. Therefore, in the present study, we attempted to
observe the expression of miR-454 in activated HSCs
and in the fibrotic livers, and then to study the role of
miR-454 on HSC activation.
Methods
Animals and Schistosoma japonicum (S. japonicum)
-infected liver fibrosis models
Healthy 4-6-wk-old male ICR mice were obtained from
the Laboratory Animal Center of Nantong University. S.
japonicum cercariae released from infected intermediate
host snail Oncomelania hupensis were provided by the
Jiangsu Institute of Parasitic Diseases (Wuxi, China). To
construct the models infected with S. japonicum, mice
were percutaneously infected with 20 ± 2 cercariae of
S. japonicum and sacrificed on the 8th week after infec-
tion. HE staining and sirius-red staining were performed
to confirm that the liver fibrosis models were con-
structed successfully. Animal care and experimental pro-
cedures were approved by the Animal Ethics Committee
of Nantong University.
Cell culture and treatment
An immortalized human HSCs line, LX-2 cell line, was
obtained from Xiang Ya Central Experiment Laboratory.
LX-2 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, Invitrogen, USA) supplemented with
10% fetal bovine serum (FBS, Invitrogen, USA) in a hu-
midified incubator at 37°C with 5% CO2. LX-2 cells were
plated in a 6-well plate and cultured for 24 h before
transfection. Then mimics, inhibitors of miR-454 or the
nonspecific (NS)-miRNA were transfected into the cells
at a final concentration of 100 nmol/l using lipofecta-
mine 2000 (Invitrogen, USA) according to the manufac-
turers instructions. The culture medium was discarded
after transfection for 4-6 h and replaced with the fresh
medium or the medium with TGF-β1 (Sigma, USA) at
the concentration of 5 ng/ml for 48 h. The sequences of
the miR-454 mimics, inhibitors and the NS-miRNA were
all designed and synthesized by Genepharma Company
in Shanghai, China.
Construction and luciferase assay of 3′-UTR of Smad4
The wild-type and mutant sequences of the 3′-UTR of
human Smad4 were amplified from LX-2 cells and
cloned into the psi-CHECK-2 luciferase vector. For
dual-luciferase reporter assays, the wild-type Luc-Smad4
or mutant Luc-Smad4 plasmids and miRNAs were co-transfected into LX-2 cells using lipofectamine 2000.
After transfection for 48 h, the cells were collected and
luciferase activity was analyzed by the dual-luciferase
assay kit (Promega, USA).
RNA isolation and quantitative real-time PCR (qRT-PCR)
Total RNA was isolated using the Trizol reagent (Invitrogen,
USA) according to the manufacturer’s instruction and then
reverse transcribed into cDNA using the Revert Aid First
Strand cDNA Synthesis Kit (Thermo Fisher Scientific,
USA). QRT-PCR was performed according to the protocol
of SYBR Premix Ex Taq RT-PCR Kit (Takara, Japan) in the
Eco Real-time PCR system (Illumina, USA). The miRNAs
were extracted using RNAiso for Small RNA (Takara, Japan)
and reverse transcribed for qRT-PCR using SYBR Prime-
Script miRNA RT-PCR integrative kit (Takara, Japan) ac-
cording to the manufacturer’s protocol. The sense primers
for miRNA qRT-PCR were synthesized by Invitrogen
(China) [10,13], and the universal anti-sense primer was
obtained from Takara.
Western blot
Proteins from LX-2 were extracted using RIPA lysis buffer
(Beyotime, China) and quantified by the Bradford method
(Sangon, China). Then the proteins were separated on
10% sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and electrotransferred onto polyvi-
nylidene fluoride (PVDF) membranes. The membranes
were blocked with 10% nonfat dry milk and then probed
with primary antibodies against α-smooth muscle actin
(α-SMA, Santa Cruz Biotechnology, USA), Smad4 (Santa
Cruz Biotechnology, USA), PCNA (Abcam, USA) and gly-
ceraldehyde phosphate dehydrogenase (GAPDH, Good-
here, China) at 4°C overnight. The membranes were then
washed and incubated with horseradish peroxidase (HRP)-
conjugated secondary antibodies. Then the membranes
were visualized with ECL-chemiluminescent kit (Merck,
Germany).
MTT assay
The cell proliferation of LX-2 was determined using
MTT assay. Firstly, the cells were plated at a density of
5 × 103 cells/well in a 96-well culture plate for 24 h.
After transfection with miR-454 mimics or NS-miRNA
for 4-6 h, the culture medium was replaced with the
fresh medium or the medium with TGF-β1. After LX-2
cells were pulsed with MTT (Sigma, USA) for 4 h, 100
μl of dimethylsulphoxide (DMSO) was added in the
medium to dissolve the formazan products. The optical
density (OD) was determined on an enzyme-linked im-
munosorbent assay (ELISA) reader (Bio-Tek) at 490 nm
wavelength. All experiments were performed in triplicate
and repeated at least three times.
Figure 1 TGF-β1 can up-regulate the expression of α-SMA in
LX-2. (A) Dose-dependent effect of TGF-β1 on α-SMA protein
expression was analyzed by Western blot. (B) Time-dependent effect
of TGF-β1 on α-SMA protein expression was analyzed by Western blot.
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The cell cycle phase was determined by fluorescence acti-
vating cell sorter (FACS) analysis with propidium iodide
(PI, Sigma, USA) staining. LX-2 cells were transfected
with miR-454 mimics or NS-miRNA and treated with or
without TGF-β1. After fixation, cells were treated with
RNase A to digest RNA in the cells and stained with PI at
37°C for 30 min. The cells were then assessed by flow cy-
tometry and the data were analyzed. All experiments were
repeated at least three times.
Statistical analysis
All experiments were performed in triplicate and the re-
sults were presented as mean ± SEM. The data were ana-
lyzed by One-Way ANOVA (LSD) using the SPSS 15.0
software to determine their significant differences. A
value of P<0.05 was considered statistically significant.
Results
α-SMA is up-regulated in TGF-β1-treated LX-2 cells
TGF-β1 is one of the most important molecules in acti-
vation of HSCs [14] and the expression of α-SMA, which
is one of the characteristics of HSC activation, can be in-
creased in HSCs treated with TGF-β1. Here, we showed
that treatment of LX-2 cells with TGF-β1 at the concen-
tration of 0, 2.5, 5 and 10 ng/ml for 48 h could result in
the increased expression of α-SMA protein (Figure 1A).
The expression of α-SMA protein in LX-2 cells was also
increased in LX-2 cells treated with TGF-β1 (5 ng/ml)
for 0, 24, 48 and 72 h (Figure 1B). The results showed
that the expression of α-SMA protein in LX-2 cells
could be up-regulated by TGF-β1 in the time- and dose-
dependent manner.
Expression of miR-454 is down-regulated in
TGF-β1-treated LX-2 cells
The expression of miR-454 in TGF-β1-treated HSCs was
evaluated by qRT-PCR. The data showed that the ex-
pression of miR-454 in LX-2 cells was also decreased
when the cells were treated with TGF-β1 at the concen-
tration of 2.5, 5 and 10 ng/ml for 48 h (Figure 2A), or
when the cells were treated with TGF-β1 (5 ng/ml) for
24, 48 and 72 h (Figure 2B).
Over-expression of miR-454 cannot regulate the
proliferation and cell cycle distribution of LX-2 cells
To investigate whether miR-454 was involved in the
proliferation of HSCs, miR-454 mimics was transiently
transfected into LX-2 cells and the results showed that
the miR-454 expression was obviously increased in the
cells with TGF-β1 and miR-454 mimics transfection,
compared with the cells transfected with NS-mimics and
TGF-β1 (Figure 3A). The down-regulation of miR-454
expression induced by TGF-β1 could be reversed in thecells transfected with miR-454 mimics, but not in the
cells transfected with NS-miRNA (Figure 3A). Then, we
analyzed whether the expression of miR-454 could affect
cellular proliferation of LX-2 by MTT assay. The results
showed that miR-454 had no effect on the proliferation
of LX-2 with the existence of TGF-β1, compared with
the group of the cells treated with TGF-β1 and NS-
miRNA (P>0.05, Figure 3B). To further observe whether
miR-454 could affect cell cycle in TGF-β1-treated LX-2
cells, we analyzed the effect of miR-454 on cell cycle of
LX-2 cells by flow cytometry. We found that miR-454
mimics had no significant effect on cell cycle distribu-
tion, compared with those cells treated with TGF-β1 and
NS-miRNA (P>0.05, Figure 3C). These data indicated
that over-expression of miR-454 could not affect the
proliferation and cell cycle distribution of TGF-β1-
treated-LX-2 cells.
Over-expression of miR-454 inhibits the expression of
α-SMA in TGF-β1-treated LX-2 cells
As shown in the results in Figure 4, the expression of
α-SMA mRNA (Figure 4A) and protein (Figure 4B) in
TGF-β1-treated LX-2 cells were both increased signifi-
cantly. The expression of α-SMA mRNA (Figure 4A)
and protein (Figure 4B) were all inhibited obviously in
Figure 2 The expression of miR-454 was down-regulated in
TGF-β1-treated LX-2 cells. (A, B) The expression of miR-454 in
LX-2 cells which were treated with TGF-β1 at the indicated concentration
or for the indicated time were detected by qRT-PCR. * P <0.05 vs control
(cells with no stimulus).
Figure 3 The effect of miR-454 on proliferation and cell cycle
distribution of TGF-β1-treated LX-2. (A) The expression of miR-454
in LX-2 cells was analyzed by qRT-PCR. The expression of miR-454
could be down-regulated in the cells treated with TGF-β1 and in the
cells co-treated with TGF-β1 and NS-miRNA. * P <0.05 vs control
(cells with no stimulus). However, the down-regulation of miR-454
expression induced by TGF-β1 could be reversed in the cells transfected
with miR-454 mimics (# P <0.05, compared with the group of the cells
co-treated with TGF-β1 and miR-454 mimics). (B) The proliferation
capacity of LX-2 cells was increased when the cells were treated with
TGF-β1. * P <0.05 vs control (cells with no stimulus). However, miR-454
mimics could not regulate the proliferation of LX-2 cells by MTT assay
(P>0.05, compared with the group of the cells co-treated with TGF-β1
and NS-miRNA). (C) The effect of miR-454 on cell cycle of LX-2 cells was
analyzed by flow cytometry. P>0.05 vs control (cells with no stimulus).
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mimics, compared with those cells transfected by NS-
miRNA and co-treated with TGF-β1. The data demon-
strated that over-expression of miR-454 significantly de-
creased the expression of α-SMA. miR-454 may be
involved in the TGF-β1-induced HSC activation.
Smad4 is a direct target of miR-454 in HSCs
Potential targets of miR-454 were then predicted using
miRbase Targets, miRanda and TargetScan 5 platform,
and Smad4 is the most attractive target of miR-454 for
further study (Figure 5A). Smad4 is a critical participator
in the regulation of TGF-β1 signaling and it has been
reported to be a target of miR-454 in colorectal cancer
cells [13]. To determine whether miR-454 could also
regulate the expression of Smad4 in HSCs, miR-454
mimics and NS-miRNA were transfected into TGF-β1-
treated LX-2 cells, respectively. The results revealed that
the expression of Smad4 protein in LX-2 cells was up-
regulated in response to TGF-β1 stimulation and this
effect could be inhibited by the mimics of miR-454
(Figure 5B).
Furthermore, in order to investigate whether Smad4 was
directly targeted by miR-454 expression, we constructedthe luciferase reporter plasmids containing wild-type or
mutant 3′-UTR sequences of Smad4. The data showed
that the luciferase reporter activity of the reporter plas-
mids containing the wild-type 3′-UTR of Smad4, but not
the mutant 3′-UTR of Smad4, could be reduced by
miR-454 mimics and increased by miR-454 inhibitor
(Figure 5C). Therefore, miR-454 could inhibit TGF-β1-
induced LX-2 activation by the suppression of Smad4
expression.
Figure 4 miR-454 mimics could inhibit TGF-β1–induced α-SMA
expression in LX-2 cells. (A) miR-454 mimics reduced the levels of
α-SMA mRNA expression in TGF-β1-treated LX-2 cells as detected by
qRT-PCR. * P <0.05 vs control (cells with no stimulus). # P <0.05 vs
the group of TGF-β1 +mimics+. (B) Western blot analysis confirmed
that α-SMA protein expression was inhibited by miR-454 mimics in
TGF-β1-treated LX-2 cells.
Figure 5 miR-454 directly targeted Smad4 in LX-2 cells.
(A) Sequence alignment of putative miR-454-binding site in the
3′-UTR of Smad4 and the sequence of the mutant 3′-UTR of Smad4
were shown. (B) The expression of Smad4 protein was reduced by
miR-454 in TGF-β1-treated LX-2 cells,as determined by Western blot.
(C) Over-expression of miR-454 could induce the decrease of the
luciferase activity of the wild-type Luc-Smad4 reporter, but not that
of the mutant-type Luc-Smad4 reporter. Meanwhile, miR-454
inhibitor could increase luciferase activity of the wild-type 3′-UTR of
Smad4. * P <0.05 vs one’s own control group (cells transfected with
NS-miRNA and wild or mutant plasmids).
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S. japonicum-induced liver fibrosis models
In addition, we also investigated the expression of miR-
454 in mouse models with liver fibrosis induced by S.
japonicum. QRT-PCR was performed to analyze the rela-
tive expression level of miR-454 in fibrotic livers. The data
clearly indicated that miR-454 was sharply declined in the
livers infected with S. japonicum for 8 weeks (Figure 6A).
Meanwhile, the results also revealed that the expression of
α-SMA and Smad4 were up-regulated significantly in the
fibrotic livers at 8 weeks post-infection, compared with
the normal livers (Figure 6B). Therefore, the results sug-
gested that miR-454 may play an important role on S.
japonicum-infected liver fibrosis.
Discussion
Liver fibrosis, which is characterized by an accumulation
of ECM, is a common response to many liver injuries.
During the progression of liver fibrosis, quiescent HSCs,
which can be provoked by hepatitis B and C viruses,
nonalcoholic steatohepatitis, alcoholism and schistosomeinfection, can activate into a myofibroblast-like pheno-
type [2,4]. Recently, some studies have focused on the
functions of miRNAs on liver fibrosis [8,9,15]. Previous
studies have shown that miR-181b expression could be
increased in HSC-T6 cells treated with TGF-β1 and
miR-181b mimics could significantly promote the proli-
feration of HSC-T6 cells by directly targeting p27 [8].
The expression of miR-150 and miR-194 were both
down-regulated in the fibrotic livers of rats induced by
bile duct-ligation (BDL), while over-expression of miR-
150 and miR-194 could inhibit the proliferation of LX-2
Figure 6 miR-454 was down-regulated in S. japonicum-infected
fibrotic livers. (A) The expression of the miR-454 was down-regulated
in the fibrotic tissues infected with S. japonicum for 8 weeks as detected
by qRT-PCR. * P <0.05 vs control (normal mice). (B) The levels of α-SMA
and Smad4 expression were all up-regulated in the fibrotic livers
infected with S. japonicum for 8 weeks as determined by Western blot.
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patic stellate cells through the PTEN/Akt pathway [16].
Consistent with the results obtained by Ji et al. [10] that
the expression of miR-454 was depressed in activated rat
HSCs, we found that the expression of miR-454 was
down-regulated in LX-2 cells treated with TGF-β1.
TGF-β1/Smads signaling pathway is a key mediator to
induce HSC activation and liver fibrosis [17]. TGF-β1 can
promote the formation of ECM through stimulation of
the synthesis and secretion of Type-1 or Type-2 collagen
and α-SMA [18,19]. In addition, previous studies have in-
dicated that anti-sense Smad4 gene could block TGF-β1
signal transduction by reducing the expression of Smad4
to inhibit the production of ECM and ameliorate hepatic
fibrosis [20-22]. In this research, we also found that TGF-
β1 could induce the activation of HSCs and reduce the
expression of miR-454. Besides these, over-expression of
miR-454 could inhibit the expression of α-SMA induced
by TGF-β1 stimulation. However, miR-454 did not affect
the proliferation and cell cycle in TGF-β1-treated LX-2
cells. Since previous studies have shown that the expres-
sion of miR-454 was significantly up-regulated in colon
cancer and in HCT116 cells, and miR-454 contributed to
colon tumorigenesis by directly repressing the expression
of Smad4 [13], we further investigated whether Smad4
was also a direct target of miR-454 to regulate the expres-
sion of α-SMA in TGF-β1-treated LX-2 cells. Our experi-
ments demonstrated that miR-454 could influence thelevel of Smad4 expression in TGF-β1-treated LX-2 cells,
and over-expression of miR-454 could inhibit the lucifer-
ase activity of the wild-type Luc-Smad4 plasmid, but not
the mutant-type Luc-Smad4 plasmid. Meanwhile, miR-
454 inhibitor could increase luciferase activity of the wild-
type 3′-UTR of Smad4 in LX-2 cells. These data indicated
that miR-454 may down-regulate the expression of α-
SMA and therefore inhibit the activation of TGF-β1-
treated HSCs by directly targeting Smad4. However, since
previous researches have found that over-expression of
miR-146a could also inhibit TGF-β1-induced HSC prolif-
eration by targeting Smad4 [11], we cannot rule out the
possibility that other miRNAs could participate in the
modulation of HSC activation and proliferation. We also
cannot rule out the possibility that miR-454 could inhibit
HSC activation through other signaling pathways, since
multiple mRNAs are predicted by some softwares to be
targeted by the same miRNA. Hence, further studies are
needed to reveal the complex relationship among miRNAs
(miR-146a and others), targets and hepatic fibrosis.
Schistosomiasis, which is caused by schistosomes, is one
of the most common causes of hepatic fibrosis. Granu-
lomatous inflammation is an initial characteristic mani-
festation of liver fibrosis induced by schistosomes.
Recently, some studies have reported that the expression
of some miRNAs can be regulated in the mouse liver in-
fected with S. japonicum, and it suggests that miRNAs
may be involved in the process of inflammatory gra-
nuloma formation and the subsequent hepatic fibrosis
[23,24]. Meanwhile, studies have also focused on the ex-
pression of miRNA profiles in the host liver infected with
schistosomes to understand the molecular mechanisms
of schistosomal hepatopathy, which differs from other
chronic hepatopathy [25]. In this study, we also observed
the expression of miR-454 in the mouse liver during S.
japonicum infection. The results showed that the level of
the miR-454 was down-regulated in the fibrotic livers
infected with S. japonicum for 8 weeks. On the contrary,
the levels of α-SMA and Smad4 expression were all up-
regulated. Since the tendency of the expression of Smad4
was opposite to that of miR-454 in the process of hepatic
fibrosis induced by S. japonicum infection, we hypothe-
sized that miR-454 may be involved in the progression of
liver fibrosis induced by S. japonicum infection through
the TGF-β1/Smad4 pathway.
Conclusions
In summary, our results indicated that miR-454 could in-
hibit the activation of HSCs by directly targeting Smad4.
Moreover, miR-454 was regulated in the process of hep-
atic fibrosis induced by S. japonicum infection. Thus,
miR-454 may provide a novel therapeutic approach for
treating liver fibrosis, especially the liver fibrosis induced
by S. japonicum.
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